Xencor (NASDAQ:XNCR) Stock Price Down 4.3% - Should You Sell?

Xencor, Inc. (NASDAQ:XNCR - Get Free Report)'s share price dropped 4.3% during trading on Friday . The stock traded as low as $8.99 and last traded at $8.88. Approximately 20,578 shares changed hands during trading, a decline of 97% from the average daily volume of 783,331 shares. The stock had previously closed at $9.28.

Wall Street Analysts Forecast Growth

Several brokerages have commented on XNCR. Wedbush restated an "outperform" rating and set a $31.00 target price on shares of Xencor in a research report on Wednesday, April 30th. Barclays lowered their target price on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a research note on Thursday, May 8th. Finally, William Blair assumed coverage on shares of Xencor in a report on Monday, April 21st. They issued an "outperform" rating on the stock. Two research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $28.00.

Xencor Trading Up 0.2%

The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.89 and a current ratio of 5.89. The stock has a market cap of $629.85 million, a P/E ratio of -2.89 and a beta of 0.85. The company has a 50-day simple moving average of $8.50 and a 200-day simple moving average of $12.72.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.06). The company had revenue of $32.73 million for the quarter, compared to analyst estimates of $23.44 million. Xencor had a negative return on equity of 31.94% and a negative net margin of 181.17%. The firm's quarterly revenue was up 104.6% on a year-over-year basis. During the same quarter last year, the company earned ($1.11) EPS. On average, sell-side analysts forecast that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Insider Transactions at Xencor

In other news, Director Ellen Feigal sold 2,993 shares of Xencor stock in a transaction on Monday, June 16th. The stock was sold at an average price of $9.22, for a total value of $27,595.46. Following the completion of the sale, the director directly owned 19,183 shares of the company's stock, valued at approximately $176,867.26. This trade represents a 13.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kurt A. Gustafson sold 2,993 shares of the company's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $9.22, for a total value of $27,595.46. Following the transaction, the director directly owned 20,183 shares in the company, valued at $186,087.26. This trade represents a 12.91% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 15,810 shares of company stock worth $154,123 in the last quarter. 5.23% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Goldman Sachs Group Inc. raised its stake in shares of Xencor by 89.9% during the first quarter. Goldman Sachs Group Inc. now owns 726,734 shares of the biopharmaceutical company's stock worth $7,732,000 after buying an additional 344,088 shares during the last quarter. Inspire Investing LLC raised its position in shares of Xencor by 85.3% during the 1st quarter. Inspire Investing LLC now owns 32,402 shares of the biopharmaceutical company's stock valued at $345,000 after acquiring an additional 14,913 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Xencor by 9.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,047 shares of the biopharmaceutical company's stock valued at $471,000 after purchasing an additional 3,692 shares during the period. Jacobs Levy Equity Management Inc. lifted its stake in shares of Xencor by 73.9% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 904,485 shares of the biopharmaceutical company's stock valued at $9,624,000 after purchasing an additional 384,509 shares during the period. Finally, BVF Inc. IL boosted its position in shares of Xencor by 19.7% in the 1st quarter. BVF Inc. IL now owns 2,740,141 shares of the biopharmaceutical company's stock worth $29,155,000 after purchasing an additional 451,381 shares during the last quarter.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.